Clinical outcomes and survival in patients with NSCLC and EGFR exon 20 mutations: evidence from real-world clinical practice in a retrospective study in Galicia
The results show the limited effectiveness of TKIs in patients with EGFR Ex20Ins and highlight the need for specific therapies. Platinum-based chemotherapy performed better in preventing disease relapse.
Authors
- Lucía Santomé Couto
- Martín Emilio Lázaro Quintela
- Francisco Javier Afonso Afonso
- Manuel Fernández-Bruno
- Cristina Azpitarte Raposeiras
- Natalia Fernández Núñez
- Ma Carmen Areses Manrique
- Raquel Romero Van der Schoot
- Jorge García-González
Institutions
- Universidade da Coruña (ES)
- University Hospital Complex Of Vigo (ES)
- Povisa Hospital (ES)
- Hospital Universitario Lucus Augusti (ES)
- Instituto de Investigación Sanitaria de Santiago (ES)
- Complejo Hospitalario de Pontevedra (ES)
- Medical Research Network (US)
- Complejo Hospitalario de Ourense (ES)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-02-23
- DOI
- https://doi.org/10.3389/fonc.2026.1677766
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00